AnalystsInsight

Chen Chen (UBS): Analyst Track Record and Price‑Target Accuracy

How often Chen Chen’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 3 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Chen Chen ranks #848 of 1,121 analysts in Exent’s scoring (4.7★).
  • 0.0% of price targets were reached over 7 years, versus 53.6% for the average analyst.
  • Median time to reach a target: — days; 100.0% of calls were up 12 months later.
  • Most‑covered stocks: HKG-9926, HKG-9995, HKG-9969, HKG-6127.
  • Free on Exent: Chen Chen’s full record, with ratings 3 days after publication.

Chen Chen’s track record at a glance

Chen Chen of UBS ranks #848 of the 1,121 analysts Exent scores, with a 4.7★ rating and a focus on healthcare. Over a 7‑year lookback, 0.0% of Chen’s price targets were reached, 53.6 points below the 53.6% average across all analysts.

MetricChen ChenAll analysts
Price‑target hit rate0.0%53.6%
Median days to hit target—91 days
Calls up after 12 months100.0%64.6%
Median 12‑month return of calls+48.2%+13.4%
Hit rate, last 2 years——
Average worst drop after a call−21.8%—
Ratings in the sample3—
Stocks covered14—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetChen Chen
Under 30 days—
30–90 days—
90–180 days—
Over 180 days—

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Chen Chen covers most

StockRatings in the sample
HKG-992618
HKG-999517
HKG-996915
HKG-612713
HKG-187711
HKG-334711
HKG-226910
HKG-22526

In the past year Chen’s ratings were 52% Buy, 48% Hold and 0% Sell.

Chen Chen’s latest ratings

DateStockActionRatingPrice target
Sep 29, 2026HKG-9926Reiterated: BuyBuy$149.00
Sep 14, 2026HKG-9926Reiterated: BuyBuy$149.00
Sep 3, 2026HKG-9926Reiterated: BuyBuy$149.00
Sep 1, 2026HKG-2269Reiterated: BuyBuy$62.00
Aug 25, 2026HKG-3759Downgraded: HoldHold$35.30
Jul 22, 2026HKG-9926Reiterated: BuyBuy$160.80
Jul 2, 2026HKG-2269Reiterated: BuyBuy$51.10
Jun 11, 2026HKG-9926Maintained: BuyBuy$185.50
Jun 11, 2026HKG-9926Reiterated: BuyBuy$185.50
Mar 27, 2026HKG-9926Maintained: BuyBuy$173.40
Mar 27, 2026HKG-9926Reiterated: BuyBuy$173.40
Mar 27, 2026HKG-9926MaintainedBuy$173.40
  • Sep 29, 2026
    Stock
    HKG-9926
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $149.00
  • Sep 14, 2026
    Stock
    HKG-9926
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $149.00
  • Sep 3, 2026
    Stock
    HKG-9926
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $149.00
  • Sep 1, 2026
    Stock
    HKG-2269
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $62.00
  • Aug 25, 2026
    Stock
    HKG-3759
    Action
    Downgraded: Hold
    Rating
    Hold
    Price target
    $35.30
  • Jul 22, 2026
    Stock
    HKG-9926
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $160.80
  • Jul 2, 2026
    Stock
    HKG-2269
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $51.10
  • Jun 11, 2026
    Stock
    HKG-9926
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $185.50
  • Jun 11, 2026
    Stock
    HKG-9926
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $185.50
  • Mar 27, 2026
    Stock
    HKG-9926
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $173.40
  • Mar 27, 2026
    Stock
    HKG-9926
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $173.40
  • Mar 27, 2026
    Stock
    HKG-9926
    Action
    Maintained
    Rating
    Buy
    Price target
    $173.40

Chen’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Oct 20, 2026; ranking updated Oct 21, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Chen Chen’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Chen Chen ranks #848 of 1,121 with a 4.7★ rating. 0.0% of price targets were reached over a 7-year lookback (all analysts: 53.6%), and 100.0% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Chen Chen’s success rate is 72.4% by the ranking source and 0.0% by Exent’s price-target hit-rate backtest, with a median of — days to reach a target.

Chen Chen (UBS) covers 14 stocks, mostly in healthcare. The most frequently rated are HKG-9926, HKG-9995, HKG-9969, HKG-6127, HKG-1877.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.